Effect of PRP injection on low back pain

The Effect of Ultrasound-Guided PRP Injection Versus Corticosteroid Injection on Pain Relief and Functional Improvement in Patients with Low Back Pain due to Lumbar Facet Joint Involvement: A Double-Blind, Non-Inferiority Clinical Trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180804040685N6

Enrollment

Registered

2026-01-19

Start date

2026-01-05

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Low Back Pain due to Lumbar Facet Joint Involvement. Low back pain

Interventions

Intervention 1: Intervention group: Initially, approximately 15 mL of peripheral venous blood will be collected from each patient using a blood collection set and sterile syringes containing an antico

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Chronic low back pain lasting more than 3 months Pain score greater than 4 on the visual analog scale (VAS > 4) Inadequate response to noninvasive and conservative treatments such as nonsteroidal anti-inflammatory drugs (NSAIDs) and physical therapy based on the patient's medical history Normal lower limb muscle strength on neurological examination Unilateral lumbar facet joint pain Local tenderness on physical examination over the facet joint and pain elicited during lumbar hyperextension maneuvers Single-level involvement of the facet joint

Exclusion criteria

Exclusion criteria: Age younger than 18 years or older than 65 years Acute low back pain with a duration of less than 3 months Pain score of 4 or =4 on the Visual Analog Scale Abnormal lower extremity muscle strength on neurological examination Involvement of more than one facet joint (multi-level involvement)

Design outcomes

Primary

Measure	Time frame
Pain intensity. Timepoint: Measurement of pain intensity at baseline (before the intervention) and at 30 and 90 days after initiation of the intervention. Method of measurement: Visual Analog Scale.;Functional disability. Timepoint: Measurement of functional disability at baseline (before the intervention) and at 30 and 90 days after initiation of the intervention. Method of measurement: Oswestry Disability Index.;Physical disability. Timepoint: Measurement of physical disability at baseline (before the intervention) and at 30 and 90 days after initiation of the intervention. Method of measurement: Roland-Morris Disability Questionnaire.	—

Measure

Time frame

Pain intensity. Timepoint: Measurement of pain intensity at baseline (before the intervention) and at 30 and 90 days after initiation of the intervention. Method of measurement: Visual Analog Scale.;Functional disability. Timepoint: Measurement of functional disability at baseline (before the intervention) and at 30 and 90 days after initiation of the intervention. Method of measurement: Oswestry Disability Index.;Physical disability. Timepoint: Measurement of physical disability at baseline (before the intervention) and at 30 and 90 days after initiation of the intervention. Method of measurement: Roland-Morris Disability Questionnaire.

—

Secondary

Measure	Time frame
Analgesic medication use. Timepoint: During the 3-month follow-up period. Method of measurement: Daily medication diary.;Adverse events and safety. Timepoint: During the 3-month follow-up period. Method of measurement: Adverse Event Checklist.;Need for additional treatments or surgical intervention. Timepoint: During the 3-month follow-up period. Method of measurement: Regular monitoring and follow-up visits by the physician/investigator.	—

Measure

Time frame

Analgesic medication use. Timepoint: During the 3-month follow-up period. Method of measurement: Daily medication diary.;Adverse events and safety. Timepoint: During the 3-month follow-up period. Method of measurement: Adverse Event Checklist.;Need for additional treatments or surgical intervention. Timepoint: During the 3-month follow-up period. Method of measurement: Regular monitoring and follow-up visits by the physician/investigator.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZahra Biglari Nejad Ghiri

Tehran University of Medical Sciences

dr.lili7264@gmail.com+98 21 8490 3222

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 7, 2026